Viridian Therapeutics, Inc.\DE (VRDN) Research & Development (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Research & Development history runs 14 years deep, the most recent figure standing at $77.6 million for Q1 2026.

• In Q1 2026, Research & Development rose 1.04% year-over-year to $77.6 million; the TTM figure through Mar 2026 stood at $260.5 million (down 4.97% YoY), while the FY2025 annual figure was $338.9 million, up 42.26% from the prior year.
• Research & Development for Q1 2026 stood at $77.6 million, up from $10.0 million in the prior quarter.
• The five-year high for Research & Development was $86.6 million in Q2 2025, with the low at $5.6 million in Q4 2022.
• The 5-year median for Research & Development is $40.9 million (2024), against an average of $47.2 million.
• The sharpest annual moves came in 2023 and 2025: Research & Development jumped 588.52% in 2023, then plunged 86.1% in 2025.
• Viridian Therapeutics, Inc.\DE's Research & Development stood at $5.6 million in 2022, then surged by 588.52% to $38.6 million in 2023, then jumped by 86.63% to $72.0 million in 2024, then slumped by 86.1% to $10.0 million in 2025, then jumped by 676.31% to $77.6 million in 2026.
• Business Quant data shows VRDN's Research & Development at $77.6 million in Q1 2026, $10.0 million in Q4 2025, and $86.3 million in Q3 2025.